2 - TI Pharma

118. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N, Uotani S, Matsuo H,
Yamaguchi Y, Tokuyama K, Nagataki S. High-dose but not low-dose dexamethasone impairs glucose
tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. j Clin Endocrinol
Metab. 1996;81(7):2621-6.
119. Besse C, Nicod N, Tappy L. Changes in insulin secretion and glucose metabolism induced by
dexamethasone in lean and obese females. Obes Res. 2005;13(2):306-11.
120. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, Butler P, Rizza R. Assessment of
beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from
intravenous and oral glucose tests. Am j Physiol Endocrinol Metab. 2007;293(1):E1-15.
121. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests
for assessment of beta -cell function: modeling analysis in normal subjects. Am j Physiol Endocrinol
Metab. 2002;283(6):E1159-66.
122. Dessein PH, joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis.
Arthritis Rheum. 2006;54(9):2765-75.
123. Stumvoll M, Goldstein Bj, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy.
Lancet. 2005;365(9467):1333-46.
124. Masuzaki H, Paterson j, Shinyama H, Morton NM, Mullins jj, Seckl jR, Flier jS. A transgenic model of
visceral obesity and the metabolic syndrome. Science. 2001;294(5549):2166-70.
125. Morton NM, Paterson jM, Masuzaki H, Holmes MC, Staels B, Fievet C et al. Novel adipose tissuemediated
resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type
1-deficient mice. Diabetes. 2004;53(4):931-8.
126. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ
hybridization study. j Clin Endocrinol Metab. 2002;87(6):2701-5.
127. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific
dysregulation of cortisol metabolism in human obesity. j Clin Endocrinol Metab. 2001;86(3):1418-
21.
128. Tomlinson jW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11beta-hydroxysteroid
dehydrogenase type 1 in adipose tissue is not increased in human obesity. j Clin Endocrinol Metab.
2002;87(12):5630-5.
129. Paterson jM, Morton NM, Fievet C, Kenyon Cj, Holmes MC, Staels B, Seckl j, Mullins jj. Metabolic
syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type
1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101(18):7088-93.
130. Tsilchorozidou T, Honour jW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome:
insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. j Clin
Endocrinol Metab. 2003;88(12):5907-13.
49
2
Chapter 2